November 7, 2012. We are deeply concerned about the current and growing risk to the U.S. pharmaceutical supply, a threat that can best be addressed through a meaningful national system to track and authenticate pharmaceutical products as they move from manufacturer to wholesaler to pharmacy to patient.
Read More »We’re Speaking Out on Health Issues
NCHR scientists and health policy experts provide written and oral statements on a wide range of topics.
Here are many of the ways we have been Speaking Out on Health Policy Issues for the last few years. Whether the topic is legislation intended to cure diseases, proposed bans on BPA or other chemicals that disrupt your hormones, the importance of including women, people of color, and patients over 65 in clinical trials, or many other topics, you’ll gain a better understanding of our evidence-based analyses by reading these letters, statements, and testimony.
Here are the ways we have been Speaking out on Medical Treatments and Products, such as prescription drugs and medical devices that the FDA is considering approving, or is considering taking off the market because of serious risks. Whether the topic is Chantix, Addyi, Yaz, Essure, or medical products you’ve never heard of, you can find out more about what is known and not known about the safety and effectiveness of a wide range of products by looking through this section of our website.
Letter to Representative Henry A. Waxman Regarding Draft Proposal of the Data Act of 2012
November 21, 2012. The National Research Center for Women & Families supports the Data Act and shares concerns about the current and growing risk of antibacterial resistance to medically important drugs as a consequence of agricultural practices.
Read More »Coalition Letter to U.S. Senators in Opposition of Efforts to Delay or Repeal Excise Tax on Medical Devices
December 19, 2012. As members of the Patient, Consumer, and Public Health Coalition, we strongly oppose efforts to delay or repeal the 2.3% excise tax on medical devices.
Read More »Testimony at FDA Public Hearing Establishing a List of Pathogens for the GAIN Act
December 18, 2012. Dr. Yttri testifies to the FDA that the growing risk of antibiotic resistant pathogens and need for development and responsible use of new antibiotics are critical public health concerns that need to be addressed.
Read More »Testimony at FDA Public Hearing on Antiseptic Preoperative Skin Preparation Products
December 10, 2012. Dr. Yttri testifies to the FDA on the serious public health issue of contamination of antiseptic products. There are several steps the FDA can take to better ensure the safety of consumers who are exposed to antiseptic preoperative skin preparation products.
Read More »